Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease
Open Access
- 27 January 2022
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 11 (2) , 247
Abstract
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease. It is characterized by a complex network of physiopathological events where oxidative stress plays a central role among other factors such as neuroinflammation and protein homeostasis. Nuclear factor-erythroid 2 p45-related factor 2 (NRF2) has a multitarget profile itself as it controls a plethora of cellular processes involved in the progression of the disease. In this line, we designed a novel family of 2-(1H-indol-3-yl)ethan-1-amine derivatives as NRF2 inducers with complementary activities. Novel compounds are based on melatonin scaffold and include, among other properties, selective monoamine oxidase B (MAO-B) inhibition activity. Novel multitarget compounds exhibited NRF2 induction activity and MAO-B selective inhibition, combined with anti-inflammatory, antioxidant, and blood–brain barrier permeation properties. Furthermore, they exert neuroprotective properties against oxidative stress toxicity in PD-related in vitro. Hit compound 14 reduced oxidative stress markers and exerted neuroprotection in rat striatal slices exposed to 6-hydroxydopamine or rotenone. In conclusion, we developed a promising family of dual NRF2 inducers and selective MAO-B inhibitors that could serve as a novel therapeutic strategy for PD treatment.Keywords
Funding Information
- Instituto de Salud Carlos III (PI17/01700)
- European Regional Development Funds (FEDER) (PI17/01700)
- Consejería de Sanidad, Comunidad de Madrid (B2017/BMD-3827)
- Ministerio de Economía y Competitividad (PID2019-110061RB-I00)
- European Cooperation in Science and Technology (CA20121)
This publication has 102 references indexed in Scilit:
- The ‘gating’ residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognitionThe FEBS Journal, 2011
- Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's diseaseBMC Medical Genetics, 2010
- Targets for neuroprotection in Parkinson's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyteProceedings of the National Academy of Sciences of the United States of America, 2009
- Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathwayBiochemical Pharmacology, 2008
- MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's PathologyPLOS ONE, 2008
- Expression of Nrf2 in Neurodegenerative DiseasesJournal of Neuropathology & Experimental Neurology, 2007
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validationJournal of Computational Chemistry, 2002
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996